Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 1802 of 6351
-
New combo aims to wipe out rare bladder cancer before surgery
Disease control Recruiting nowThe goal of this clinical trial is to learn about the efficacy and safety of neoadjuvant adebrelimab plus etoposide and cisplatin in patients with neuroendocrine bladder carcinoma. The main questions it aims to answer are: * The pathologic complete response rate at radical cyste…
Phase 2 • Sponsor: RenJi Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
New asthma drug shows promise in early trial
Disease control CompletedThis is a Phase 2a, multicentre, randomised, placebo-controlled, double-blind, parallel-group study to evaluate the efficacy, safety and PK of AZD4604 administered BID using a dry-powder inhaler at one dose level over a 12-week Treatment period in adult participants with uncontro…
Phase 2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Experimental combo targets Hard-to-Treat pancreatic cancer
Disease control OngoingThis study is being done to test the safety and effectiveness of combining ZN-c3 and Gemcitabine in participants with pancreatic cancer. The names of the study drugs involved in this study are: * ZN-c3 (a small molecule inhibitor of the WEE1 tyrosine kinase) * Gemcitabine (a nu…
Phase 2 • Sponsor: Brandon Huffman, MD • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Can a computer program help MS patients sleep better?
Symptom relief OngoingThe goal of this randomized controlled trial is to test the effectiveness of digital cognitive behavioral therapy for insomnia (dCBT-I) compared with digital patient education about insomnia for people with Multiple Sclerosis (MS). The main questions it aims to answer are whether…
Sponsor: St. Olavs Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 12:02 UTC
-
Could early gut bacteria shape a Child's health? a 3-Year study seeks answers
Knowledge-focused By invitation onlyThis prospective observational birth cohort study aims to characterize the longitudinal development of the gut microbiome during early childhood and to investigate its associations with prenatal, perinatal, and postnatal exposures and child growth and health outcomes. Approximat…
Sponsor: Children's Hospital of Fudan University • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC
-
New ultrasound technique could end the need for surgery to diagnose endometriosis
Diagnosis By invitation onlyEndometriosis is a benign gynecological disease characterized by uterine-like cells growing outside the uterus, leading to pain, infertility, and inflammation. Endometriosis most commonly occurs in the forms of Superficial Endometriosis (SE), Deep Endometriosis and Ovarian Endome…
Sponsor: McMaster University • Aim: Diagnosis
Last updated Jun 27, 2026 13:04 UTC
-
AI and MRI join forces to spare cervical cancer patients from bladder and bowel harm
Symptom relief Recruiting nowConcurrent chemoradiotherapy (CCRT), consisting of external beam radiotherapy (EBRT) and chemotherapy, followed by brachytherapy (BT) is the standard of care for patients with locally advanced cervical carcinoma. In current clinical practice, conventionally, one radiotherapy plan…
Sponsor: Juergen Debus • Aim: Symptom relief
Last updated Jun 27, 2026 11:00 UTC
-
New pill could offer relief for chronic hives sufferers
Disease control OngoingThe purpose of the core phase of the trial is to assess the efficacy, safety and tolerability of remibrutinib (LOU064) 25 milligrams (mg) twice a day (b.i.d.) over placebo for 24 weeks and in comparison to omalizumab 300 mg every 4 weeks (q4w) for 52 weeks in participants with ch…
Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Nasal spray could tame brain inflammation in progressive MS
Disease control OngoingForalumab is a human anti-CD3 monoclonal antibody being developed for the treatment of autoimmune and inflammatory diseases. The goal of this Phase 2a, randomized, double-blind placebo-controlled, multicenter dose-ranging study is to evaluate the use of nasal foralumab in patien…
Phase 2 • Sponsor: Tiziana Life Sciences LTD • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New stent aims to keep multiple heart arteries open
Disease control By invitation onlyThe investigators intend to establish a multicenter prospective observational study by enrolling and tracking patients with multivessel coronary artery disease (MVCAD) using Genoss DES, a device manufactured with pure domestic technology. The study aims to evaluate the efficacy a…
Sponsor: Genoss Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Can a cancer drug ease long COVID? new trial tests LAU-7b
Symptom relief CompletedESSOR is a double-blind, placebo-controlled study of the orally-administered antiviral and inflammation-controlling LAU-7b for the treatment of adults with Long COVID and moderate to severe symptoms.
Phase 2/3 • Sponsor: Laurent Pharmaceuticals Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 08:08 UTC
-
New rehab program shows promise for long COVID sufferers
Symptom relief CompletedAbout 10-20% of persons who contract SARS CoV-2 will experience persistent post-acute sequelae of SARSCoV-2 infection (referred here as PASC). While treatments offered at emerging outpatient COVID recovery clinics are being informed by previous similar diseases, the need is great…
Sponsor: University of Pennsylvania • Aim: Symptom relief
Last updated Jun 27, 2026 08:12 UTC
-
Diabetes pills may fight fatty liver, study finds
Disease control CompletedStudy question 1:Could SGLT2-I improve hepatic fibrosis, steatosis, and inflammatory markers in type 2 diabetic patients with Metabolic associated steatotic liver disease Question 2:Which drug of SGLT2-I group is more effective in improving metabolic associated steatotic liver di…
Phase 3 • Sponsor: Sohag University • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
AI coaches doctors on cancer risk talks
Knowledge-focused Recruiting nowIn this pilot study, the investigators will show feasibility of the NLP-based feedback system in 20 consultations of men with newly diagnosed prostate cancer. The investigators will recruit from the practices of up to 10 physicians who typically see these patients. The investigat…
Sponsor: Cedars-Sinai Medical Center • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
Old gout drug may tame deadly heart inflammation
Disease control Recruiting nowTwo-parallel groups randomized, single-blinded, multi-center phase III controlled trial in patients with chronic inflammatory cardiomyopathy to assess the efficacy of colchicine and associated prospective registry to assess the prognostic value of positive genetic testing in this…
Phase 3 • Sponsor: Niguarda Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
Hospitals join forces to hunt down missed diagnoses
Knowledge-focused Recruiting nowThis study seeks to link a group of hospitals to measure and share the rates of diagnostic errors, to understand underlying causes of diagnostic errors, and develop ways that hospitals, clinicians, and patients can work together to avoid diagnostic errors and harms due to those e…
Sponsor: Brigham and Women's Hospital • Aim: Knowledge-focused
Last updated Sep 09, 2026 23:00 UTC
-
New hope for myeloma patients as platform trial tests multiple treatments
Disease control Recruiting nowCO43923 is a platform study that will evaluate the safety, efficacy, and pharmacokinetics (PK) of multiple treatment combinations, as monotherapy or in combination, in participants with multiple myeloma (MM). The study is designed with the flexibility to open new treatment substu…
Phase 1/2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New combo therapy offers hope for kids with tough leukemia
Disease control Recruiting nowHEM-iSMART is a master protocol which investigates multiple investigational medicinal products in children, adolescents and young adults (AYA) with relapsed/refractory (R/R) ALL and LBL. Sub-protocol D is a phase I/II trial evaluating the safety and efficacy of trametinib in comb…
Phase 1/2 • Sponsor: Princess Maxima Center for Pediatric Oncology • Aim: Disease control
Last updated Jun 26, 2026 18:46 UTC
-
Which pathology method spots more cancer spread?
Knowledge-focused Recruiting nowIn general, the European pathological examination method primarily relies on pathologists and does not require the involvement of surgeons. The Japanese pathological evaluation approach, on the other hand, involves the intervention of surgeons, particularly in the extraction of l…
Phase 3 • Sponsor: Russian Society of Colorectal Surgeons • Aim: Knowledge-focused
Last updated Aug 19, 2026 00:00 UTC
-
Radioactive cocktail targets Hard-to-Treat breast cancer
Disease control OngoingThe purpose of this trial is to estimate the recommended dose (RD) of \[177Lu\]Lu-NeoB in combination with ribociclib and fulvestrant in participants with estrogen receptor (ER) positive (ER+), human epidermal growth factor receptor-2 (HER2) negative (HER2-) and gastrin releasing…
Phase 1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC